Pluripotent stem cell-derived NK progenitor cell therapy prevents tumour occurrence and eradicates minimal residual disease
Wang, Z.; Lin, Y.; Huang, D.; Zhang, L.; Xia, C.; Weng, Q.; Liu, Y.; Wang, T.; Zhang, M.; Wu, J.; Qi, H.; Liu, L.; Shen, Y.; Chen, Y.; Zhu, Y.; Hu, F.; Wang, J.
Show abstract
The lack of persistence and short-term efficacy presents a major challenge for CAR-NK cell therapy. Here, we addressed this issue by developing pluripotent stem cell-derived NK lineage-committed progenitor (iNKP) cell therapy. For the first time, we generated abundant iNKP cells via an organoid culture system. The iNKP cells, engineered to express CXCR4 and chimeric antigen receptors (CAR), efficiently migrated to the bone marrow and generated CAR-iNK cells persisting in peripheral blood (PB) for over 80 days. Notably, CAR-iNKP cell therapy durably protected animals from tumour occurrence. Furthermore, a single low-dose infusion of CAR-iNKP cells following conventional chemotherapy eradicated minimal residual disease (MRD), leading to long-term complete remission. Our findings present a novel strategy to overcome the limitations of traditional CAR-NK cell therapy and offer dural breakthroughs for the prevention of tumour occurrence and relapse.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of leukemia 97%
- Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in JAK2-mutant myeloproliferative neoplasms 96%
- An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer 96%
Similar papers in this journal
- The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1 96%
- Single cell dissection of developmental origins and transcriptional heterogeneity in B-cell acute lymphoblastic leukemia 95%
- Extracellular 2’3’-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.